EMEA-003423-PIP02-23 - paediatric investigation plan
volrustomig
PIPHuman
Key facts
- Active Substance
- volrustomig
- Therapeutic area
- Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- Decision number
- P/0070/2024
- PIP number
- EMEA-003423-PIP02-23
- Pharmaceutical form(s)
- Concentrate for solution for injection/infusion
- Condition(s) / indication(s)
- Treatment of head and neck epithelial malignant neoplasms
- Route(s) of administration
- Intravenous use
- Contact for public enquiries
AstraZeneca AB
E-mail: paediatrics@astrazeneca.com
- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date